Al-Habib resumes operations after expansion

The Dr. Sulaiman Al-Habib Medical Group reported record quarterly revenues exceeding 4 billion SAR during the second quarter of 2026, representing an 18.4% year-over-year growth. The increase in patient visits and improved utilization of expansion assets contributed to this revenue boost, especially in the hospital sector, which saw a 17.1% growth, and in demand for medications and related services, which rose by 21.6%. Although EBITDA (earnings before interest, taxes, depreciation, and amortization) increased by 21.4% to 1.04 billion SAR, net profit grew by only 12.1%, reaching 662.7 million SAR. This indicates that operational improvements have not fully translated into higher net profits; while operational margins recovered, depreciation expenses and other costs continued to hinder substantial growth in net profit. Overall, the results demonstrate that the company is beginning to benefit from its expansion efforts through increased bed utilization, but it remains essential to continue growing the patient base and convert operational growth into accelerated increases in profits and net cash flows during the second half of 2026.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل